Comparison · NCT00505778-sae
Mesalamine Once-Daily vs Mesalamine Twice-Daily: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Mesalamine Once-Daily vs Mesalamine Twice-Daily: serious adverse events. Trial comparisons, record NCT00505778-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00505778-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0352 | 0.0224 | 0.0549 | wilson | |
| Risk in group 2 | 0.0176 | 0.00929 | 0.0331 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0175 | -0.00257 | 0.039 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2 | 0.905 | 4.4 | log | |
| Odds ratio, group 1 over group 2 | 2.03 | 0.904 | 4.57 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Mesalamine Once-Daily than on Mesalamine Twice-Daily | 57 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Mesalamine Once-Daily | an oral, once daily (QD) mesalamine regimen (1.6 - 2.4 g/day) | 18 | 512 | EG000 |
| Group 2 | Mesalamine Twice-Daily | an oral, twice daily (BID) mesalamine regimen (1.6 - 2.4 g/day) | 9 | 511 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 12 months
Source ClinicalTrials.gov
Trial
- Title
- A Comparison of Once a Day Dose Compared to 2 Doses/Day
- NCT number
- NCT00505778
- Phases
- PHASE3
- Conditions
- Ulcerative Colitis
- Interventions
- Mesalamine Once-Daily, Mesalamine Twice-Daily
- Lead sponsor
- Warner Chilcott
- Results first posted
- 2011-05-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00505778?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00505778-sae